4DMedical shares (ASX: 4DX) stumbled today, closing 8.16% lower at A$4.05, as markets took profits following one of the ASX’s most spectacular rallies in recent memory.
The medical technology company emerged as the ASX’s biggest laggard for the session, with 4DX share price sliding to A$4.05. Despite the pullback, the broader picture remains remarkable: 4DMedical has surged 209% over the past six months and an extraordinary 965% over the past twelve months, transforming from a speculative biotech into one of the market’s standout performers.
Markets appear to be reassessing valuations after the stock’s meteoric rise, particularly following the company’s A$150 million capital raising completed on January 15, 2026, at A$3.80 per share.
4DMedical’s remarkable ascent has been underpinned by a series of transformative milestones that have fundamentally altered the company’s commercial trajectory. The respiratory imaging specialist has successfully transitioned its flagship CT:VQ technology from early-stage development to genuine market deployment across multiple jurisdictions.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The most recent catalyst arrived in December 2025, when Health Canada granted regulatory approval for CT:VQ, enabling immediate commercial deployment through the company’s partnership with Philips. The Canadian market represents substantial opportunity, with over 560 CT scanners installed and potential for more than 800,000 CT:VQ procedures annually. Markets responded enthusiastically at the time, driving shares up 22.13% to A$2.98 on the announcement.
Earlier regulatory wins have proven equally significant. In September 2025, 4DMedical secured FDA clearance for CT:VQ and, critically, gained reimbursement eligibility from the U.S. Centers for Medicare & Medicaid Services. This combination unlocked the vast American healthcare market, where reimbursement pathways are essential for commercial viability.
The company’s financial performance has reflected this operational progress. Half-year results for the period ending December 31, 2024, showed operating revenue of A$3.8 million, representing a 265.3% increase from the prior corresponding period. Gross margins remained stable above 90%, while net operating expenditure of A$18.8 million marked an 11% reduction from the previous half-year, demonstrating improving cost discipline as revenues scale.
4DMedical has secured validation from respected industry players. In July 2025, Pro Medicus committed A$10 million in strategic investment to accelerate CT:VQ commercialization, lending credibility to the technology’s market potential. The relationship with Pro Medicus, a successful Australian healthtech company, provides both capital and strategic expertise.
The company has remained active in capital markets to fund its expansion. Beyond the recent A$150 million raise, 4DMedical completed a A$5.5 million placement at A$0.425 per share in February 2025, accompanied by a Share Purchase Plan underwritten to A$7 million. The frequency and scale of capital raises reflect both the cash-intensive nature of medical technology commercialization and markets’ willingness to fund the growth story.
Outlook
The current pullback appears driven by profit-taking rather than fundamental deterioration. Markets that have delivered 965% returns inevitably face periods of consolidation as early investors crystallize gains and new buyers assess entry points. The A$150 million capital raising at A$3.80 per share has created a natural reference point, with the stock now trading above that level despite recent weakness.
The commercial pathway ahead remains compelling but uncertain. Regulatory approvals in Canada, the United States, and other jurisdictions have opened addressable markets worth hundreds of millions in potential annual revenue. However, translating regulatory clearance into actual clinical adoption requires successful execution on sales, training, and integration with existing hospital workflows.
Reimbursement eligibility represents a necessary but insufficient condition for success. Healthcare providers must be convinced that CT:VQ delivers clinical value justifying adoption, while radiology departments must integrate the technology into established protocols. The partnership with Philips provides distribution infrastructure, but revenue ramp timing remains difficult to forecast with precision.
Today’s decline underscores the double-edged nature of 4DMedical’s volatility: the same momentum that delivered extraordinary gains can reverse swiftly when sentiment shifts. With regulatory milestones largely achieved and commercialization now the focus, markets will demand evidence that CT:VQ can convert approvals into sustainable revenue growth, making the coming quarters critical for determining whether recent gains represent justified optimism or excessive exuberance.
